Myogenic differentiation of human amniotic mesenchymal cells and its tissue repair capacity on volumetric muscle loss.

ABSTRACT: Stem cell-based tissue engineering therapy is the most promising method for treating volumetric muscle loss. Human amniotic mesenchymal cells possess characteristics similar to those of embryonic stem cells. In this study, we verified the stem cell characteristics of human amniotic mesenchymal cells by the flow cytometry analysis, and osteogenic and adipogenic differentiation. Through induction with the DNA demethylating agent 5-azacytidine, human amniotic mesenchymal cells can undergo myogenic differentiation and express skeletal muscle cell-specific markers such as desmin and MyoD. The Wnt/β-catenin signaling pathway also plays an important role. After 5-azacytidine-induced human amniotic mesenchymal cells were implanted into rat tibialis anterior muscle with volumetric muscle loss, we o

SUBMITTER: Zhang D 

PROVIDER: S-EPMC6851610 | biostudies-literature | 2019 Jan-Dec

REPOSITORIES: biostudies-literature